New Lek Board of Management begins working today
Ljubljana, August 1 – New Board of Management of Lek Pharmaceuticals d. d. starts working today. It includes Vojmir Urlep, President of the Board of Management, and members Darija Brečevič, Ksenija Butenko Černe, Markus Delfosse, Marjan Novak, who is also Workers’ Director, and Anette Weber. Term of office of the members of the Board of Management is 5 years.
At its meeting July 10, the Supervisory Board of Lek, a Sandoz company, approved the expansion of the company Board of Management in accordance with the appointment of Vojmir Urlep, who succeeds Janja Bratoš in the position of President of the Board of Management
In addition to the two new members – Markus Delfosse, responsible for technical operations, and Darija Brečevič, responsible for human resources – the Lek Board of Management will continue to include present members Ksenija Butenko Černe, Member of the Board of Management responsible for managing and ensuring the legal harmonization of the operations of the company with relevant local and EU legislation and for the operations of the company as a good corporate citizen, a member of the Novartis/Sandoz group, Marjan Novak, Member of the Board of Management and Workers’ Director, and Anette Weber, Member of the Board of Management responsible for finance.
The Lek Shareholders’ Assembly appointed new member to the Supervisory Board on July 13. The newly appointed member of the Supervisory Board is Gerhard Schaefer, Head Global Product Development in Sandoz, who will replace outgoing member Markus Delfosse.
Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. It operates as a global development center for products and technologies, as a global manufacturing center for active pharmaceutical ingredients and medicines, as a competence center for the development of vertically integrated products, as a Sandoz competence center in the field of development and manufacturing of biopharmaceutical products and as a supply center for the markets of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz’s global markets. Lek d.d. employs about 2,820 people and achieved total sales of USD 904 million in 2006. For further information please consult http://www.lek.si
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 840 active substances in over 5 000 forms worldwide. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these drugs along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to the strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and EonLabs (U.S.) and sells its products in more than 110 countries. In 2006, Sandoz employed around 21,000 people worldwide and posted sales of USD 6 billion.
Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics and leading self-medication OTC brands. In 2006, the Group’s businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For further information contact:
Katarina Klemenc Dinjaški
Lek Pharmaceuticals d.d.
Phone: + 386 1 580 22 43
Fax: + 386 1 580 24 32